{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diarrhoea-antibiotic-associated/prescribing-information/metronidazole/","result":{"pageContext":{"chapter":{"id":"4f209e3e-56a5-5f47-859e-8b6f0b9b9fe9","slug":"metronidazole","fullItemName":"Metronidazole","depth":2,"htmlHeader":"<!-- begin field f884cbfc-d7c2-4ad8-955c-1579d28ec5d4 --><h2>Metronidazole</h2><!-- end field f884cbfc-d7c2-4ad8-955c-1579d28ec5d4 -->","summary":"","htmlStringContent":"<!-- begin item 62cebbe9-ce8d-40fb-ad07-b7e29b08f347 --><!-- end item 62cebbe9-ce8d-40fb-ad07-b7e29b08f347 -->","topic":{"id":"e3d5d597-cb8d-5009-95be-96d5f61f622c","topicId":"60505e59-3d44-4100-ba77-670b2dda81a3","topicName":"Diarrhoea - antibiotic associated","slug":"diarrhoea-antibiotic-associated","lastRevised":"Last revised in November 2020","chapters":[{"id":"ff00d31e-fff0-5539-893c-63eaae28aa91","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d4f02cb1-a605-5763-85b8-7e30efe0b52d","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"b4be21a4-fea2-52ee-99b9-6ad9b7f42b37","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"14b5fd2c-0a9a-58b3-af3b-54e8f6c587a3","slug":"changes","fullItemName":"Changes"},{"id":"86cd74d6-6f35-5de4-9031-55397958409b","slug":"update","fullItemName":"Update"}]},{"id":"d9b8d789-d6e6-5a0f-80ef-2853843c67b6","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"93a9787b-a3ca-5bd2-9dd1-e7bd5ebd7e61","slug":"goals","fullItemName":"Goals"},{"id":"712c6134-ba14-5e2a-987b-8d3c06033ee0","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"04b62294-302f-5852-90f5-60c1f9593a96","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"98b4954c-4b96-5b7a-9888-99cfd0b2ce3d","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"7f04cf05-c2de-5fb3-9f58-b7e32b7a8604","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d849aa0f-051e-5e61-8d05-6da99fdc60e0","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"146be3ba-ef2c-5d7c-a6be-75d743b6cbdb","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3deeffef-b60e-557b-a9ce-2ca055de0653","slug":"definition","fullItemName":"Definition"},{"id":"788d8348-35a0-5147-b765-a90a068257b9","slug":"prevalence","fullItemName":"Prevalence"},{"id":"7804f825-6a78-5c22-89f7-9ecb4f2ac588","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"4d2b177e-1c5d-5783-b256-b0b7173e4660","slug":"complications","fullItemName":"Complications"},{"id":"0d3b3c20-ff70-5653-9cb1-750667c15098","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"db6311c9-b63f-5037-89f3-fe2ed41761c7","fullItemName":"Management","slug":"management","subChapters":[{"id":"1ddecd55-2bf4-53db-8594-8c1489126404","slug":"diarrhoea-antibiotic-associated","fullItemName":"Scenario: Diarrhoea - antibiotic associated"}]},{"id":"e0650ec6-ca9b-5cf0-9761-2ffe00571666","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"4f209e3e-56a5-5f47-859e-8b6f0b9b9fe9","slug":"metronidazole","fullItemName":"Metronidazole"}]},{"id":"1a19af07-ea9e-59ac-8ce6-508d4d01e536","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ecd4dd69-cf4c-507f-9659-b23f2a5b3272","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"b0079d2b-b8c1-59e3-a1c1-f6f2c83a07c5","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"919502d7-1740-58a4-8ea5-2feeb47d6e28","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"d1844305-0beb-50de-a2de-fbea6a58b880","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"766c971f-c448-56d3-a9d4-2ffded846f90","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"7d18a1e0-eeb3-5b2f-bd26-e9f231d83c40","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"99309640-cab2-57c4-8bd0-2c05065abd69","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e0650ec6-ca9b-5cf0-9761-2ffe00571666","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"8d708688-b5c0-5c0d-a254-f0627eae9f10","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field fdfad2a3-1094-4a34-8a3f-a9ff015ccf51 --><h3>What are the cautions and contraindications with metronidazole?</h3><!-- end field fdfad2a3-1094-4a34-8a3f-a9ff015ccf51 -->","summary":"","htmlStringContent":"<!-- begin item 52cf4015-d454-49e5-884e-a9ff015ccf09 --><!-- begin field 948d0e1a-8375-45f9-a469-a9ff015ccf51 --><ul><li><strong>Do not prescribe metronidazole in people with:</strong><ul><li>Known metronidazole or nitroimidazole hypersensitivity.</li></ul></li><li><strong>Prescribe metronidazole with caution in people with:</strong><ul><li>Cockayne syndrome — cases of severe hepatotoxicity/acute hepatic failure, including cases with a fatal outcome with very rapid onset after treatment initiation in patients with Cockayne syndrome have been reported with products containing metronidazole for systemic use. <ul><li>Only prescribe after careful benefit-risk assessment and only if no alternative treatment is available. Liver function tests must be performed just prior to the start of therapy, throughout and at the end of treatment until liver function is within normal ranges, or until the baseline values are reached. Discontinue metronidazole if liver function tests become markedly elevated during treatment.</li></ul></li><li>Active or chronic severe peripheral and central nervous system disease, as there is a risk of neurological aggravation.</li><li>Severe liver disease or hepatic encephalopathy — prescribe one-third of the daily dosage once daily.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">ABPI, 2018b</a>]</p><!-- end field 948d0e1a-8375-45f9-a469-a9ff015ccf51 --><!-- end item 52cf4015-d454-49e5-884e-a9ff015ccf09 -->","subChapters":[]},{"id":"50edccd0-05e5-5ae8-a6e8-56dafedcfd90","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 014863d4-35fc-42fd-adb2-a9ff015ce538 --><h3>What are the adverse effects of metronidazole?</h3><!-- end field 014863d4-35fc-42fd-adb2-a9ff015ce538 -->","summary":"","htmlStringContent":"<!-- begin item 966cf042-8e5d-43fa-a40c-a9ff015ce516 --><!-- begin field 8143b68f-2ab1-4549-a278-a9ff015ce538 --><ul><li><strong>Blood disorders </strong>— agranulocytosis, neutropenia, thrombocytopenia, pancytopenia (very rare).</li><li><strong>Eye </strong>— transient diploplia, or myopia (very rare).</li><li><strong>Gastrointestina</strong>l — nausea, vomiting, diarrhoea, anorexia, epigastric pain, taste disturbances, furred tongue, oral mucositis (unknown frequency).</li><li><strong>Nervous system</strong> — drowsiness, dizziness, convulsions, headaches, encephalopathy (very rare).</li><li><strong>Psychiatric</strong> — confusion, hallucinations (very rare).</li><li><strong>Skin</strong> — rash, pruritus, flushing, erythema multiforme, Stevens-Johnson syndrome or toxic epidermal necrolysis, fixed drug eruption (very rare or frequency unknown).</li><li><strong>Other rare, or very rare adverse effects include:</strong><ul><li>Anaphylaxis.</li><li>Darkening of urine.</li><li>Hearing impairment, tinnitus (frequency unknown).</li><li>Liver enzyme increases, jaundice, pancreatitis.</li><li>Myalgia, arthralgia.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">BNF 76, 2018</a>]</p><!-- end field 8143b68f-2ab1-4549-a278-a9ff015ce538 --><!-- end item 966cf042-8e5d-43fa-a40c-a9ff015ce516 -->","subChapters":[]},{"id":"fb55036d-a5d9-512d-ae83-7e3631b79361","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field abbbe10c-5b30-40e8-9450-a9ff015d0ade --><h3>What drug interactions are associated with metronidazole?</h3><!-- end field abbbe10c-5b30-40e8-9450-a9ff015d0ade -->","summary":"","htmlStringContent":"<!-- begin item 83a101dc-782b-443c-9385-a9ff015d0ac0 --><!-- begin field 54f182c2-f0f0-4db5-a2bb-a9ff015d0ade --><ul><li><strong>Alcohol </strong>— some people taking metronidazole experience a disulfiram-like reaction with alcohol.<ul><li>Warn the person that they <em>might </em>experience this reaction if they drink alcohol whilst on metronidazole and for at least 48 hours afterwards. </li></ul></li><li><strong>Busulfan </strong>— Metronidazole increases the risk of toxicity with busulfan. The manufacturer advises monitoring.</li><li><strong>Ciclosporin </strong>— levels of ciclosporin may be increased. If co-administration of metronidazole and ciclosporin is necessary, serum ciclosporin levels and serum creatinine should be closely monitored.</li><li><strong>5-fluorouracil</strong> — metronidazole reduces the clearance of 5-fluorouracil, increasing the risk of toxicity.</li><li><strong>Lithium </strong>— metronidazole has been reported to increase the risk of lithium retention and renal damage. The manufacturer advises tapering or withdrawing lithium treatment before administering metronidazole. Plasma concentrations of lithium, creatinine, and electrolytes should be monitored if metronidazole and lithium are used simultaneously.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of metronidazole.<ul><li>However, women should be advised about the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.  </li></ul></li><li><strong>Phenobarbital </strong>— the metabolism of metronidazole is increased significantly. </li><li><strong>Warfarin</strong> — the anticoagulant effects of warfarin may be increased by metronidazole. <ul><li>Monitor the international normalized ratio (INR) and adjust the warfarin dose accordingly. </li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">BNF 76, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">FSRH, 2017</a>]</p><!-- end field 54f182c2-f0f0-4db5-a2bb-a9ff015d0ade --><!-- end item 83a101dc-782b-443c-9385-a9ff015d0ac0 -->","subChapters":[]},{"id":"1f6c98e3-c508-5d3d-a2b2-a4b252ea2cda","slug":"pregnancy-breastfeeding","fullItemName":"Pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 1bc9d0ee-0354-4a2e-a1bc-a9ff015d3397 --><h3>Are there issues prescribing metronidazole in pregnancy and breastfeeding?</h3><!-- end field 1bc9d0ee-0354-4a2e-a1bc-a9ff015d3397 -->","summary":"","htmlStringContent":"<!-- begin item c9f4ccff-3886-4f15-b1cb-a9ff015d3378 --><!-- begin field 3c3cdcca-416f-496c-b672-a9ff015d3397 --><h4>Pregnancy</h4><ul><li>Although there is limited evidence on the safety of metronidazole in pregancy, it has been widely used without apparent ill consequence. However the manufacturer advises that it should only be used if the benefit outweighs the risk and that a single high-dose regimen should be avoided.<ul><li>Data for oral metronidazole use in pregnancy do not suggest an increased risk of congenital malformation, low birth weight, intrauterine death, or neonatal complications, although data are conflicting regarding risk of spontaneous abortion.</li></ul></li></ul><h4>Breastfeeding</h4><ul><li>The British National Formulary states that significant amounts of metronidazole are present in breastmilk and large single doses should be avoided, however it is otherwise compatible with breastfeeding (although milk may have a bitter taste) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">BNF 76, 2018</a>].</li><li>The manufacturer advises avoiding use during lactation unless considered essential and does not recommend short, high-dosage regimens [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">ABPI, 2018b</a>].  </li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">UKTIS, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">ABPI, 2018b</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diarrhoea-antibiotic-associated/references/\">BNF 76, 2018</a>]</p><!-- end field 3c3cdcca-416f-496c-b672-a9ff015d3397 --><!-- end item c9f4ccff-3886-4f15-b1cb-a9ff015d3378 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}